{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:01:42Z","timestamp":1793192502377,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"21","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2025,6,11]]},"DOI":"10.1038\/s41388-025-03336-w","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:37:22Z","timestamp":1741394242000},"page":"1609-1619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["ROS-ATM-CHK2 axis stabilizes HIF-1\u03b1 and promotes tumor angiogenesis in hypoxic microenvironment"],"prefix":"10.1038","volume":"44","author":[{"given":"Ming","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengzhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunrun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-9070","authenticated-orcid":false,"given":"Ning","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6606-327X","authenticated-orcid":false,"given":"Xiaoyu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6471-1993","authenticated-orcid":false,"given":"Liu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"3336_CR1","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1101\/gad.1243304","volume":"18","author":"AJ Giaccia","year":"2004","unstructured":"Giaccia AJ, Simon MC, Johnson R. The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease. Genes Dev. 2004;18:2183\u201394.","journal-title":"Genes Dev"},{"key":"3336_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"3336_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393\u2013410.","journal-title":"Nat Rev Cancer"},{"key":"3336_CR4","doi-asserted-by":"publisher","first-page":"884","DOI":"10.5551\/jat.RV17009","volume":"24","author":"H Abe","year":"2017","unstructured":"Abe H, Semba H, Takeda N. The roles of hypoxia signaling in the pathogenesis of cardiovascular diseases. J Atheroscler Thromb. 2017;24:884\u201394.","journal-title":"J Atheroscler Thromb"},{"key":"3336_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.15252\/emmm.201404271","volume":"7","author":"A McIntyre","year":"2015","unstructured":"McIntyre A, Harris AL. Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med. 2015;7:368\u201379.","journal-title":"EMBO Mol Med"},{"key":"3336_CR6","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1158\/1078-0432.CCR-11-2390","volume":"18","author":"M DeLay","year":"2012","unstructured":"DeLay M, Jahangiri A, Carbonell WS, Hu YL, Tsao S, Tom MW, et al. Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res. 2012;18:2930\u201342.","journal-title":"Clin Cancer Res"},{"key":"3336_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","volume":"20","author":"C Viallard","year":"2017","unstructured":"Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409\u201326.","journal-title":"Angiogenesis"},{"key":"3336_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(00)81957-1","volume":"98","author":"GL Semenza","year":"1999","unstructured":"Semenza GL. Perspectives on oxygen sensing. Cell. 1999;98:281\u20134.","journal-title":"Cell"},{"key":"3336_CR9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.1066373","volume":"294","author":"RK Bruick","year":"2001","unstructured":"Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337\u201340.","journal-title":"Science"},{"key":"3336_CR10","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1152\/physiol.00001.2004","volume":"19","author":"GL Semenza","year":"2004","unstructured":"Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology. 2004;19:176\u201382.","journal-title":"Physiology"},{"key":"3336_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271\u20135.","journal-title":"Nature"},{"key":"3336_CR12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","volume":"2","author":"L Schito","year":"2016","unstructured":"Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer. 2016;2:758\u201370.","journal-title":"Trends Cancer"},{"key":"3336_CR13","doi-asserted-by":"publisher","first-page":"13047","DOI":"10.1074\/jbc.M513033200","volume":"281","author":"HJ Kang","year":"2006","unstructured":"Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, Cho CH, et al. BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem. 2006;281:13047\u201356.","journal-title":"J Biol Chem"},{"key":"3336_CR14","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/sj.emboj.7600196","volume":"23","author":"M Koshiji","year":"2004","unstructured":"Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 2004;23:1949\u201356.","journal-title":"EMBO J"},{"key":"3336_CR15","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/carcin\/bgn231","volume":"29","author":"R Wirthner","year":"2008","unstructured":"Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts. Carcinogenesis. 2008;29:2306\u201316.","journal-title":"Carcinogenesis"},{"key":"3336_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/jmcb\/mju045","volume":"6","author":"L Zannini","year":"2014","unstructured":"Zannini L, Delia D, Buscemi G. CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol. 2014;6:442\u201357.","journal-title":"J Mol Cell Biol"},{"key":"3336_CR17","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1128\/MCB.24.2.708-718.2004","volume":"24","author":"J Zhang","year":"2004","unstructured":"Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol. 2004;24:708\u201318.","journal-title":"Mol Cell Biol"},{"key":"3336_CR18","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1038\/sj.onc.1202925","volume":"18","author":"P Chaturvedi","year":"1999","unstructured":"Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene. 1999;18:4047\u201354.","journal-title":"Oncogene"},{"key":"3336_CR19","doi-asserted-by":"publisher","first-page":"6819","DOI":"10.1128\/MCB.00562-06","volume":"26","author":"Y Pereg","year":"2006","unstructured":"Pereg Y, Lam S, Teunisse A, Biton S, Meulmeester E, Mittelman L, et al. Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage. Mol Cell Biol. 2006;26:6819\u201331.","journal-title":"Mol Cell Biol"},{"key":"3336_CR20","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/ncb869","volume":"4","author":"S Yang","year":"2002","unstructured":"Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1\/Chk2. Nat Cell Biol. 2002;4:865\u201370.","journal-title":"Nat Cell Biol"},{"key":"3336_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ncb974","volume":"5","author":"C Stevens","year":"2003","unstructured":"Stevens C, Smith L, La Thangue NB. Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol. 2003;5:401\u20139.","journal-title":"Nat Cell Biol"},{"key":"3336_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.canlet.2018.05.047","volume":"431","author":"H Kim","year":"2018","unstructured":"Kim H, Lin Q, Yun Z. The hypoxic tumor microenvironment in vivo selects tumor cells with increased survival against genotoxic stresses. Cancer Lett. 2018;431:142\u20139.","journal-title":"Cancer Lett"},{"key":"3336_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.biochi.2019.01.004","volume":"158","author":"SH Kim","year":"2019","unstructured":"Kim SH, Kil IS, Kwon OS, Kang BS, Lee DS, Lee HS, et al. Oxalomalate reduces tumor progression in melanoma via ROS-dependent proapoptotic and antiangiogenic effects. Biochimie. 2019;158:165\u201371.","journal-title":"Biochimie"},{"key":"3336_CR24","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/35103059","volume":"2","author":"J Bartek","year":"2001","unstructured":"Bartek J, Falck J, Lukas J. CHK2 kinase-a busy messenger. Nat Rev Mol Cell Biol. 2001;2:877\u201386.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3336_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1404","volume":"2","author":"B Dai","year":"2011","unstructured":"Dai B, Zhao XF, Mazan-Mamczarz K, Hagner P, Corl S, Bahassi el M, et al. Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma. Nat Commun. 2011;2:402.","journal-title":"Nat Commun"},{"key":"3336_CR26","doi-asserted-by":"publisher","first-page":"19253","DOI":"10.1074\/jbc.272.31.19253","volume":"272","author":"BH Jiang","year":"1997","unstructured":"Jiang BH, Zheng JZ, Leung SW, Roe R, Semenza GL. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem. 1997;272:19253\u201360.","journal-title":"J Biol Chem"},{"key":"3336_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.trecan.2019.08.005","volume":"5","author":"D Mennerich","year":"2019","unstructured":"Mennerich D, Kubaichuk K, Kietzmann T. DUBs, hypoxia, and cancer. Trends Cancer. 2019;5:632\u201353.","journal-title":"Trends Cancer"},{"key":"3336_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13644","volume":"7","author":"HT Wu","year":"2016","unstructured":"Wu HT, Kuo YC, Hung JJ, Huang CH, Chen WY, Chou TY, et al. K63-polyubiquitinated HAUSP deubiquitinates HIF-1alpha and dictates H3K56 acetylation promoting hypoxia-induced tumour progression. Nat Commun. 2016;7:13644.","journal-title":"Nat Commun"},{"key":"3336_CR29","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176:1248\u201364.","journal-title":"Cell"},{"key":"3336_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1158\/1078-0432.CCR-17-1318","volume":"24","author":"AL Casillas","year":"2018","unstructured":"Casillas AL, Toth RK, Sainz AG, Singh N, Desai AA, Kraft AS, et al. Hypoxia-inducible PIM kinase expression promotes resistance to antiangiogenic agents. Clin Cancer Res. 2018;24:169\u201380.","journal-title":"Clin Cancer Res"},{"key":"3336_CR31","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605\u201322.","journal-title":"Cancer Cell"},{"key":"3336_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1515\/jbcpp-2017-0167","volume":"30","author":"TA Ajith","year":"2018","unstructured":"Ajith TA. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer. J Basic Clin Physiol Pharmacol. 2018;30:11\u201318.","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"3336_CR33","doi-asserted-by":"publisher","first-page":"33095","DOI":"10.1074\/jbc.M605058200","volume":"281","author":"I Mylonis","year":"2006","unstructured":"Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, Kalousi A, et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem. 2006;281:33095\u2013106.","journal-title":"J Biol Chem"},{"key":"3336_CR34","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.4161\/cc.26930","volume":"12","author":"NA Warfel","year":"2013","unstructured":"Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS. CDK1 stabilizes HIF-1alpha via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle. 2013;12:3689\u2013701.","journal-title":"Cell Cycle"},{"key":"3336_CR35","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cbin.10922","volume":"42","author":"M Bai","year":"2018","unstructured":"Bai M, Song N, Che X, Wang X, Qu X, Liu Y. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer. Cell Biol Int. 2018;42:781\u201393.","journal-title":"Cell Biol Int"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03336-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03336-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:40:25Z","timestamp":1747806025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-025-03336-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":35,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,6,11]]}},"alternative-id":["3336"],"URL":"https:\/\/doi.org\/10.1038\/s41388-025-03336-w","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}